News

BlogsPosts
Press Release
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Results from both trials will support commercialization initiatives, partner discussions and continued clinical development VANCOUVER, BC
BlogsPosts
Press Release
Replicel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
VANCOUVER, BC – April 8, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
VANCOUVER, BC – April 6, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
Investor Hub News Releases Financials Analyst Coverage Events SEDAR Filings EDGAR Filings Presentations & Fact Sheets Corporate Governance Info Request Videos RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
BlogsPosts
Press Release
RepliCel Announces CEO Update
Milestones for 2016 include two clinical trial readouts, finalizing RCI-02 for a 2017 product launch,
BlogsPosts
Press Release
RepliCel Life Sciences Announces Warrant Exercise Incentive Program
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY,
BlogsPosts
Press Release
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
BlogsPosts
Press Release
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Leadership Transition
Lee Buckler, former VP Business & Corporate Development, appointed CEO President & Director; David Hall
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR
BlogsPosts
Press Release
First Participants Enrolled in RepliCel’s Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable
Testing the use of a cell-based injectable as a regenerative alternative for the global dermal
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATES
BlogsPosts
Press Release
Industry Leader Geoff MacKay Joins RepliCel Life Sciences’ Board of Directors
VANCOUVER, BC – October 15, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),
BlogsPosts
Press Release
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
Clinical trial site located at IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany VANCOUVER, BC –
BlogsPosts
Press Release
RepliCel Life Sciences Cleared to Initiate Clinical Trial of RCS-01 for Dermal Rejuvenation
Patient recruitment will take place at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany
BlogsPosts
Press Release
RepliCel Reports Second Quarter 2015 Financial Results
VANCOUVER, BC – August 28, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),
BlogsPosts
Press Release
RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype
Novel features of next-generation design promise to serve and expand the dermal injectable market VANCOUVER, BC
BlogsPosts
Press Release
RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin
BlogsPosts
Press Release
RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis
ReaCT Trial at University of British Columbia Treating Patients with Autologous CellTherapy VANCOUVER, BC – June

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.